Aarti Drugs Ltd
Aarti Drugs Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #50 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Aarti Drugs Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Net Revenue from Operations: Rs. 826.2 Crore, up 27% YoY from Rs. 652.8 Crore in Q2 FY26 (Page 8). Q2 FY27 EBITDA: Rs. 137.9 crore, up 63% YoY from Rs. 84.4 crore.
From Aarti Drugs Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Aarti Drugs' revenue grow in the September 2026 quarter?
- Q2 FY27 Net Revenue from Operations: Rs. 826.2 Crore, up 27% YoY from Rs. 652.8 Crore in Q2 FY26 (Page 8).
- H1 FY27 Net Revenue from Operations: Rs. 1,529.0 Crore, up 23% YoY from Rs. 1,243.3 Crore in H1 FY26 (Page 8).
- Volume growth has been consistent despite pricing pressures, with a 7% volume growth reported in FY26 (Page 12).
2 more points from Aarti Drugs Ltd's call on revenue
Create a free account to keep reading this call
What happened to Aarti Drugs' margins in Q2 FY27?
See what Aarti Drugs Ltd said on profitability & margins — free account, 30 seconds.
What capex is Aarti Drugs planning?
- Completed capex of Rs. 600 crores focused on capacity and margin boost.
- Operationalized two greenfield facilities:
- Sayakha Amines (manufactures Di-, Mono-, Tri-methylamines, key for APIs like Metformin).
- Tarapur Salicylic Acid facility; operations scale-up in progress.
- Sayakha facility aims at backward integration; strategic importance emphasized.
- Anti-diabetic segment:
- Current capacity ~1,400 TPM; scaling to 2,000–2,200 TPM at existing site.
- Additional 800 TPM brownfield expansion underway; ~500 TPM targeted for USFDA markets.
- Construction completion expected in 6–8 months; expected margin expansion and cost control benefits.
- Anti-protozoals segment:
- Capacity increase by ~40% in Indian market; approval obtained for China market entry.
- Anti-inflammatory segment:
- Multi-purpose facility under construction; brownfield expansion ongoing.
2 more points from Aarti Drugs Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Aarti Drugs raising money or cutting debt?
See what Aarti Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Aarti Drugs' order book?
See what Aarti Drugs Ltd said on order book & pipeline — free account, 30 seconds.
Aarti Drugs Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹720 Cr, net profit ₹55 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aarti Drugs's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aarti Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aarti Drugs Ltd Q2 FY27 results?
Q2 FY27 Net Revenue from Operations: Rs. 826.2 Crore, up 27% YoY from Rs. 652.8 Crore in Q2 FY26 (Page 8). Q2 FY27 EBITDA: Rs. 137.9 crore, up 63% YoY from Rs. 84.4 crore.
What is Aarti Drugs Ltd share price analysis?
Aarti Drugs Ltd currently shows a neutral. The stock trades at a P/E of 22.1 with a market cap of ₹4,256 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aarti Drugs Ltd planning capital expenditure?
Completed capex of Rs. 600 crores focused on capacity and margin boost.
Keep Aarti Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.